AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Running, not enrolling · Phase 2/Phase 3

Conditions studied: Duchenne Muscular Dystrophy

In brief

RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.

Key facts

Study ID
NCT05693142
Run by
REGENXBIO Inc.
People needed
65
Starts
2023-01-04
Expected to finish
2028-06-01
Last updated by the study team
2026-07-21

Who can join

Age: 1 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.